APP Knockout HEK293 Cell Line

APP Knockout HEK293 Cell Line
Cat.No.:

EDC09598

Species:

Human

Cell Name:

HEK293

Gene:

APP

Gene ID:

351

Size:

1×10⁶cells

APP Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
Cat.No. EDC09598
Product Name APP Knockout Cell Line (HEK293)
Cell Line HEK293
Cellosaurus ID CVCL_0045
Cell Line Synonyms Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293
Gene APP
NCBI Gene ID
351
Gene Synonyms AAA|ABETA|ABPP|AD1|APPI|CTFgamma|CVAP|PN-II|PN2|alpha-sAPP|preA4
Summary
This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]
Associated Diseases Non-tumor
Morphology Adherent
Passage Ratio 1/5,2days
Complete Culture Medium DMEM + 10% FBS
Freezing Medium 95% Complete culture medium+ 5% DMSO
QC Indels validated by Sanger sequencing; sterility confirmed via microbial testing.
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
LociSTR Info (Sample Cell)
Sample Cell Line: HEK293
STR Info (Cell bank)
Cell Line: HEK293
Allele1Allele2Allele1Allele2
Amelogenin X X
CSF1P0 12 11 12
D2S1338 19 19
D3S1358 15 17 15 17
D5S818 8 8 9
D7S820 11 12 11 12
D8S1179 12 14 12 14
D13S317 12 14 12 14
D16S539 9 13 9 13
D18S51 17 18 17 18
D19S433 15 18 15 18
D21S11 28 30.2 28 30.2
FGA 23 23
Penta D 9 10 9 10
Penta E 7 15 7 15
TH01 7 9.3 7 9.3
TPOX 11 11
vWA 16 19 16 19
D6S1043 11 11
D12S391 19 21 11 15
D2S441 11 15 11 15
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.

FAQ

The choice depends on whether you are studying APP (amyloid precursor protein)'s role as the principal precursor of Aβ peptides or modeling Alzheimer's disease (AD). The Knockout line is the standard tool for asking whether APP is required for these processes — APP is a type I transmembrane glycoprotein processed by α-secretase (ADAM10, non-amyloidogenic) or sequentially by β-secretase (BACE1) and γ-secretase (presenilin complex) to generate amyloidogenic Aβ peptides (Aβ40, Aβ42); Aβ42 oligomerization and plaque deposition are central to Alzheimer's pathology. APP mutations (Swedish KM670/671NL, London V717I, Arctic E693G, others) cause familial early-onset AD. Overexpression is useful for studying APP gain-of-function effects. For Alzheimer's disease research, the EDITGENE APP Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies. Rescue with wild-type, Swedish mutation (increases Aβ production), or A673T protective mutation (Icelandic variant reducing Aβ) enables comprehensive AD modeling. The knockout is a critical specificity tool for ⭐⭐⭐ anti-Aβ antibodies: ⭐⭐⭐ lecanemab (Leqembi, FDA-approved 2023), donanemab (Kisunla, FDA-approved 2024), aducanumab (Aduhelm, withdrawn 2024); ⭐ BACE1 inhibitors (verubecestat, lanabecestat — abandoned in late-stage trials); γ-secretase modulators; emerging APP-targeted strategies.
Primary applications: • Aβ production: Aβ40, Aβ42 quantification by ELISA in conditioned media — APP KO abolishes Aβ production. • α/β/γ-secretase pathway dissection: sAPPα (α-secretase product), sAPPβ (β-secretase product), AICD (C-terminal intracellular domain) analysis. • Familial AD mutation rescue: Swedish (KM670/671NL, increases Aβ), London (V717I, increases Aβ42/Aβ40 ratio), Arctic (E693G), A673T (Icelandic protective) mutations. • Anti-Aβ antibody specificity: ⭐⭐⭐ lecanemab (Leqembi), donanemab (Kisunla), aducanumab specificity testing. • BACE1/γ-secretase inhibitor specificity: critical genetic control given APP is the principal pathological substrate. EDITGENE recommends this HEK293-based model as a critical specificity control for Alzheimer's disease drug development and Aβ biology research.
Yes. APP rescue experiments are gold-standard for Alzheimer's disease research: • Construct design: use a codon-modified APP sequence with a small intracellular C-terminal tag (FLAG, HA, after AICD). APP is a type I transmembrane glycoprotein — preserve membrane topology and secretase cleavage sites. • Familial AD mutation rescue: Swedish KM670/671NL (increases all Aβ), London V717I (increases Aβ42/Aβ40 ratio), Arctic E693G (oligomerization-prone), Icelandic A673T (protective, reduces Aβ). • Surface localization validation: confirm plasma membrane APP and proper secretase processing. • Functional readout: rescue should restore Aβ40, Aβ42 production measured by conditioned media ELISA. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for Alzheimer's disease drug development.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.

Related Publications

IF=11.5
Biomarker research
BACKGROUND:Activating the ubiquitin-proteasome system to dismantle disease- related proteins such as tau, β-amyloid, APP, and α-synuclein is an important focus in the research of neurodegenerative proteinopathy. By analyzing the serum RNA extracted from wild-type and Alzheimer's disease (AD) transgenic mice at different ages (4, 8, and 12 months), this study revealed a new protective role of FBXL16 in AD, primarily through facilitating the degradation of disease-related proteins via the ubiquitin proteasome system. METHODS:Proteomic analysis were conducted using protein lysates from HEK293 cells overexpressing FBXL16 to identify potential interacting proteins that interact with FBXL16. Subsequent experiments demonstrated that FBXL16 promotes the proteasomal degradation of the APP protein, as evidenced by co-immunoprecipitation with MG132 and cycloheximide (CHX), immunohistochemistry (IHC) and immunocytochemistry (ICC). Memory and cognitive improvements were observed in 3×Tg AD mice through the use of a lentivirus-mediated approach to generate a brain-specific AD mouse model overexpressing FBXL16 via stereotaxic injection. Furthermore, a brain-specific conditional knockout (cko) FBXL16 mouse model was generated and employed to further confirm the functional role of FBXL 16 in AD via various behavioral tests including Morris water maze and Y-maze. RESULTS:The level of FBXL16 in the brains of transgenic APP/PSEN mice with AD decreased with age. Accelerated degradation of APP was observed when FBXL16 was overexpressed in the hippocampi of these AD mice via a lentivirus. This process led to notable improvements in cognitive impairments and reductions in neuroinflammation. Further studies using proteomics and bioinformatics techniques identified transcription factors and binding proteins associated with FBXL16, providing deeper insights into the potential role of FBXL16 in the regulation of AD. Finally, the in vivo effects of FBXL16 deficiency were further substantiated in cko mice, which overexpress Aβ but specifically lack FBXL16 in the brain region. CONCLUSIONS:These findings suggest that FBXL16 could be a new regulator of AD. These findings provide a foundation for further research into drug development and potential therapeutic strategies to combat other related neurodegenerative proteinopathies.
IF=3.1
Journal of Alzheimer's disease : JAD
BACKGROUND:Neuropathological features of Alzheimer's disease are characterized by the deposition of amyloid-β (Aβ) plaques and impairments in synaptic activity and memory. However, we know little about the physiological role of amyloid-β protein precursor (AβPP) from which Aβ derives. OBJECTIVE:Evaluate APP deficiency induced alterations in neuronal electrical activity and mitochondrial protein expression. METHODS:Utilizing electrophysiological, biochemical, pharmacological, and behavioral tests, we revealed aberrant local field potential (LFP), extracellular neuronal firing and levels of mitochondrial proteins. RESULT:We show that APP knockout (APP-/-) leads to increased gamma oscillations in the medial prefrontal cortex (mPFC) at 1-2 months old, which can be restored by baclofen (Bac), a γ-aminobutyric acid type B receptor (GABABR) agonist. A higher dose and longer exposure time is required for Bac to suppress neuronal firing in APP-/- mice than in wild type animals, indicating enhanced GABABR mediated activity in the mPFC of APP-/- mice. In line with increased GABABR function, the glutamine synthetase inhibitor, L-methionine sulfonate, significantly increases GABABR levels in the mPFC of APP-/- mice and this is associated with a significantly lower incidence of death. The results suggest that APP-/- mice developed stronger GABABR mediated inhibition. Using HEK 293 as an expression system, we uncover that AβPP functions to suppress GABABR expression. Furthermore, APP-/- mice show abnormal expression of several mitochondrial proteins. CONCLUSION:APP deficiency leads to both abnormal network activity involving defected GABABR and mitochondrial dysfunction, suggesting critical role of AβPP in synaptic and network function.
This KO model may be useful for: - Investigating the role of APP in regulating gamma oscillations and GABABR-mediated inhibition in the medial prefrontal cortex - Studying mitochondrial protein expression abnormalities linked to APP deficiency - Evaluating GABABR agonist (e.g., baclofen) efficacy in models of altered neuronal network activity - Exploring the ubiquitin-dependent degradation of APP via FBXL16 as a mechanism in neuroinflammation and Alzheimer's disease - Assessing glutamine synthetase inhibition effects on GABABR levels and neuronal survival in APP-deficient contexts

Required Accessories

Related Products

Flash CRISPR Knockout Kit(Universal Version)Flash CRISPR Knockout Kit(Universal Version)
Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)

Related Services

Knockout Cell LineKnockout Cell Line
Contact Us
*
*
*
*
How did you hear about us: